MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Verve Therapeutics Inc

Open

5.79 1.94

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.51

Max

5.93

Schlüsselkennzahlen

By Trading Economics

Einkommen

98K

-50M

Verkäufe

6.2M

13M

EPS

-0.58

Gewinnspanne

-382.531

Angestellte

274

EBITDA

789K

-54M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+361.61% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

8. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-171M

424M

Vorheriger Eröffnungskurs

3.85

Vorheriger Schlusskurs

5.79

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

Verve Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Apr. 2025, 23:54 UTC

Heiße Aktien

Stocks to Watch: Alphabet, Intel, AppFolio

24. Apr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24. Apr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. Apr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24. Apr. 2025, 23:37 UTC

Top News

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24. Apr. 2025, 23:36 UTC

Top News

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24. Apr. 2025, 23:13 UTC

Top News
Ergebnisse

Google's Earnings Power Holds Up in Global Turbulence -- Update

24. Apr. 2025, 23:09 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24. Apr. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24. Apr. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24. Apr. 2025, 22:51 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24. Apr. 2025, 22:48 UTC

Top News

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24. Apr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24. Apr. 2025, 22:38 UTC

Market Talk
Ergebnisse

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24. Apr. 2025, 22:24 UTC

Ergebnisse

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24. Apr. 2025, 22:24 UTC

Ergebnisse

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24. Apr. 2025, 22:24 UTC

Market Talk
Ergebnisse

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24. Apr. 2025, 22:23 UTC

Ergebnisse

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24. Apr. 2025, 22:11 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

24. Apr. 2025, 22:11 UTC

Market Talk
Ergebnisse

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24. Apr. 2025, 22:09 UTC

Top News
Ergebnisse

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24. Apr. 2025, 22:00 UTC

Market Talk
Ergebnisse

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24. Apr. 2025, 21:39 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24. Apr. 2025, 21:24 UTC

Top News
Ergebnisse

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24. Apr. 2025, 21:24 UTC

Top News
Ergebnisse

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24. Apr. 2025, 21:23 UTC

Top News
Ergebnisse

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24. Apr. 2025, 21:04 UTC

Ergebnisse

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24. Apr. 2025, 21:03 UTC

Ergebnisse

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24. Apr. 2025, 21:03 UTC

Ergebnisse

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24. Apr. 2025, 21:02 UTC

Ergebnisse

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Peer-Vergleich

Kursveränderung

Verve Therapeutics Inc Prognose

Kursziel

By TipRanks

361.61% Vorteil

12-Monats-Prognose

Durchschnitt 25.25 USD  361.61%

Hoch 39 USD

Tief 15 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Verve Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

9

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

4.78 / 5.9576Unterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Very Strong Bearish Evidence

Langfristig

Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.